康那香 9919 - 股息配發率

現金殖利率: 1.37%、總殖利率: 1.37%、5年平均現金配發率: 93.81%
要留意資產負債表的未分配盈餘和配息能力, 如果為負值, 可能會無法發放股利
股利有2個稅要支出, 分別是綜合所得稅和健保補充保費(單筆股利達2萬元以上, 課2.11%)

	EPS YoY		現金股利 YoY		現金配發率 YoY		全部配發率 YoY
2023 (10)	3.37	0	0.30	100.0	8.90	0	8.90	0
2022 (9)	-1.34	0	0.15	-50.0	0.00	0	0.00	0
2021 (8)	0.50	-88.86	0.30	-90.0	60.00	-10.2	60.00	-10.2
2020 (7)	4.49	7383.33	3.00	1400.0	66.82	-79.96	66.82	-79.96
2019 (6)	0.06	0	0.20	0.0	333.33	0	333.33	0
2018 (5)	-0.08	0	0.20	-42.86	0.00	0	0.00	0
2017 (4)	0.58	0	0.35	75.0	60.34	0	60.34	0
2016 (3)	-2.26	0	0.20	-33.33	0.00	0	0.00	0

每股盈餘-近20季

	EPS QoQ YoY			本業EPS QoQ YoY			累計EPS QoQ YoY
23Q4 (20)	-0.58	-110.43	1.69	-0.51	85.91	-8.51	3.37	-14.68	351.49
23Q3 (19)	5.56	587.72	2085.71	-3.62	-535.09	-828.21	3.95	345.34	626.67
23Q2 (18)	-1.14	-142.55	-185.0	-0.57	-23.91	-23.91	-1.61	-242.55	-242.55
23Q1 (17)	-0.47	20.34	-571.43	-0.46	2.13	-170.59	-0.47	64.93	-571.43
22Q4 (16)	-0.59	-110.71	-5800.0	-0.47	-20.51	-2450.0	-1.34	-78.67	-368.0
22Q3 (15)	-0.28	30.0	-300.0	-0.39	15.22	-143.75	-0.75	-59.57	-244.23
22Q2 (14)	-0.40	-471.43	-202.56	-0.46	-170.59	-209.52	-0.47	-571.43	-179.66
22Q1 (13)	-0.07	-600.0	-135.0	-0.17	-950.0	-180.95	-0.07	-114.0	-135.0
21Q4 (12)	-0.01	85.71	-101.01	0.02	112.5	-97.37	0.50	-3.85	-88.89
21Q3 (11)	-0.07	-117.95	-103.24	-0.16	-138.1	-112.8	0.52	-11.86	-85.19
21Q2 (10)	0.39	95.0	-59.79	0.42	100.0	-56.7	0.59	195.0	-56.3
21Q1 (9)	0.20	-79.8	-47.37	0.21	-72.37	-44.74	0.20	-95.56	-47.37
20Q4 (8)	0.99	-54.17	518.75	0.76	-39.2	261.9	4.50	28.21	7400.0
20Q3 (7)	2.16	122.68	2063.64	1.25	28.87	1350.0	3.51	160.0	3610.0
20Q2 (6)	0.97	155.26	1485.71	0.97	155.26	1485.71	1.35	255.26	13400.0
20Q1 (5)	0.38	137.5	375.0	0.38	80.95	533.33	0.38	533.33	375.0
19Q4 (4)	0.16	245.45	0.0	0.21	310.0	0.0	0.06	160.0	0.0
19Q3 (3)	-0.11	-57.14	0.0	-0.10	-42.86	0.0	-0.10	-1100.0	0.0
19Q2 (2)	-0.07	-187.5	0.0	-0.07	-216.67	0.0	0.01	-87.5	0.0
19Q1 (1)	0.08	0.0	0.0	0.06	0.0	0.0	0.08	0.0	0.0

年/月	營收	月增率(%)	去年同期年增率(%)	累計營收	累計營收年增率(%)	近三月累計營收	存貨銷售比	備註(年增率變動50%需說明原因)
2024/3	2.33	31.09	-12.45	7.0	-10.3	7.0	N/A	-
2024/2	1.78	-38.45	-27.93	4.67	-9.18	7.03	N/A	-
2024/1	2.89	22.68	8.12	2.89	8.12	7.37	N/A	-
2023/12	2.36	11.2	-10.68	29.61	-11.81	6.94	1.08	-
2023/11	2.12	-13.87	-20.89	27.25	-11.91	7.24	1.04	-
2023/10	2.46	-7.44	-15.67	25.14	-11.05	7.65	0.98	-
2023/9	2.66	5.15	-17.37	22.68	-10.52	7.55	1.15	-
2023/8	2.53	6.7	-15.12	20.02	-9.53	7.59	1.15	-
2023/7	2.37	-12.14	-23.53	17.49	-8.66	7.52	1.16	-
2023/6	2.7	9.86	-1.67	15.12	-5.79	7.31	1.14	-
2023/5	2.45	13.38	9.53	12.42	-6.63	7.28	1.15	-
2023/4	2.16	-18.75	14.41	9.97	-9.91	7.3	1.15	-
2023/3	2.66	7.91	-12.29	7.81	-14.92	7.81	1.14	-
2023/2	2.47	-7.65	-5.57	5.14	-16.22	7.78	1.14	-
2023/1	2.67	1.33	-24.13	2.67	-24.13	7.99	1.11	-
2022/12	2.64	-1.51	-22.86	33.58	-16.63	8.23	1.16	-
2022/11	2.68	-8.18	-16.47	30.94	-16.06	8.81	1.08	-
2022/10	2.92	-9.3	-10.74	28.26	-16.02	9.11	1.05	-
2022/9	3.22	8.01	-12.12	25.34	-16.58	9.29	1.08	-
2022/8	2.98	-3.85	-6.64	22.13	-17.2	8.82	1.14	-
2022/7	3.1	12.96	8.61	19.15	-18.63	8.08	1.25	-
2022/6	2.74	22.39	-11.09	16.05	-22.39	6.87	1.42	-
2022/5	2.24	18.43	-50.66	13.31	-24.36	7.17	1.37	係因集團受疫情影響
2022/4	1.89	-37.71	-29.41	11.07	-15.22	7.54	1.3	-
2022/3	3.04	16.18	-6.32	9.18	-11.55	9.18	1.03	-
2022/2	2.61	-25.81	-4.64	6.14	-13.93	9.56	0.99	-
2022/1	3.52	3.03	-19.73	3.52	-19.73	10.15	0.93	-
2021/12	3.42	6.65	-15.02	40.28	-20.81	9.9	1.01	-
2021/11	3.21	-1.88	-15.47	36.86	-21.31	10.14	0.98	-
2021/10	3.27	-10.71	-22.34	33.65	-21.82	10.12	0.98	-
2021/9	3.66	14.75	-22.56	30.38	-21.77	9.7	1.05	-
2021/8	3.19	11.85	-29.37	26.72	-21.66	9.13	1.11	-
2021/7	2.85	-7.53	-39.64	23.53	-20.48	10.48	0.97	-
2021/6	3.08	-32.08	-30.76	20.68	-16.84	10.31	1.0	-
2021/5	4.54	69.44	4.52	17.6	-13.8	10.46	0.99	-
2021/4	2.68	-17.33	-38.86	13.05	-18.76	8.66	1.19	-
2021/3	3.24	18.26	-28.54	10.37	-11.21	10.37	1.06	-
2021/2	2.74	-37.55	-18.94	7.13	-0.21	11.16	0.99	-
2021/1	4.39	9.07	16.6	4.39	16.6	12.21	0.9	-
2020/12	4.03	6.08	13.15	50.87	25.41	12.03	0.91	-
2020/11	3.79	-9.85	14.45	46.84	26.59	12.73	0.86	-
2020/10	4.21	-10.95	18.61	43.05	27.78	13.45	0.81	-
2020/9	4.73	4.65	17.29	38.84	28.86	13.97	0.72	-
2020/8	4.52	-4.4	26.69	34.11	30.65	13.7	0.73	-
2020/7	4.73	6.05	48.72	29.59	31.27	13.53	0.74	-
2020/6	4.46	2.53	47.76	24.87	28.41	13.18	0.75	-
2020/5	4.34	-0.89	33.37	20.41	24.84	13.27	0.74	-
2020/4	4.38	-3.38	53.55	16.07	22.72	12.3	0.8	受新冠肺炎影響致營收增加
2020/3	4.54	34.15	31.87	11.69	14.12	11.69	0.72	-
2020/2	3.38	-10.16	29.76	7.15	5.14	10.7	0.79	-
2020/1	3.77	5.85	-10.16	3.77	-10.16	10.64	0.79	-
2019/12	3.56	7.3	12.97	40.56	14.73	10.42	0.91	-
2019/11	3.32	-6.58	22.61	37.0	14.91	10.89	0.87	-
2019/10	3.55	-11.94	21.93	33.69	14.2	11.14	0.85	-
2019/9	4.03	13.04	27.79	30.14	13.35	10.77	0.85	-
2019/8	3.57	12.21	13.11	26.11	11.41	9.76	0.94	-
2019/7	3.18	5.37	0.27	22.54	11.15	9.45	0.97	-
2019/6	3.02	-7.45	24.52	19.37	13.16	9.13	1.02	-
2019/5	3.26	14.1	20.24	16.35	11.29	0.0	N/A	-
2019/4	2.86	-17.02	3.76	13.09	9.27	0.0	N/A	-